Literature DB >> 26811664

Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.

Wei Kang1, Alfred S L Cheng1, Jun Yu1, Ka Fai To1.   

Abstract

More evidence has underscored the importance of Hippo signaling pathway in gastrointestinal tissue homeostasis, whereas its deregulation induces tumorigenesis. Yes-associated protein 1 (YAP1) and its close paralog TAZ, transcriptional co-activator with a PDZ-binding motif, function as key effectors negatively controlled by the Hippo pathway. YAP1/TAZ exerts oncogenic activities by transcriptional regulation via physical interaction with TEAD transcription factors. In various cancers, Hippo pathway cross-talks with pro- or anti-tumorigenic pathways such as GPCR, Wnt/β-catenin, Notch and TGF-β signaling and is deregulated by multiple factors including cell density/junction and microRNAs. As YAP1 expression is significantly associated with poor prognosis of gastric and other gastrointestinal cancers, detailed delineation of Hippo regulation in tumorigenesis provides novel insight for therapeutic intervention. In current review, we summarized the recent research progresses on the deregulation of Hippo pathway in the gastrointestinal tract including stomach and discuss the molecular consequences leading to tumorigenesis.

Entities:  

Keywords:  Hippo signaling pathway; MicroRNA; Oncogenic role; Tumor suppressor; Yes-associated protein 1

Mesh:

Substances:

Year:  2016        PMID: 26811664      PMCID: PMC4716037          DOI: 10.3748/wjg.v22.i3.1279

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  126 in total

1.  Structural and functional analysis of the YAP-binding domain of human TEAD2.

Authors:  Wei Tian; Jianzhong Yu; Diana R Tomchick; Duojia Pan; Xuelian Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

2.  TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.

Authors:  Qun-Ying Lei; Heng Zhang; Bin Zhao; Zheng-Yu Zha; Feng Bai; Xin-Hai Pei; Shimin Zhao; Yue Xiong; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2008-01-28       Impact factor: 4.272

3.  Identification of RUNX3 as a component of the MST/Hpo signaling pathway.

Authors:  Boram Min; Min-Kyu Kim; Joo-Won Zhang; Jiyeon Kim; Kwang-Chul Chung; Byung-Chul Oh; Gary S Stein; Yong-Hee Lee; Andre J van Wijnen; Suk-Chul Bae
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

4.  MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1.

Authors:  Jun Deng; Wan Lei; Xiaojun Xiang; Ling Zhang; Feng Yu; Jun Chen; Miao Feng; Jianping Xiong
Journal:  Tumour Biol       Date:  2015-04-07

5.  The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation.

Authors:  Michele I Vitolo; Ian E Anglin; William M Mahoney; Keli J Renoud; Ronald B Gartenhaus; Kurtis E Bachman; Antonino Passaniti
Journal:  Cancer Biol Ther       Date:  2007-03-01       Impact factor: 4.742

6.  Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation.

Authors:  Piotr M Wierzbicki; Krystian Adrych; Dorota Kartanowicz; Marcin Stanislawowski; Anna Kowalczyk; Janusz Godlewski; Iwona Skwierz-Bogdanska; Krzysztof Celinski; Tomasz Gach; Jan Kulig; Bartlomiej Korybalski; Zbigniew Kmiec
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

7.  Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis.

Authors:  Stefano Piccolo; Michelangelo Cordenonsi; Sirio Dupont
Journal:  Clin Cancer Res       Date:  2013-06-24       Impact factor: 12.531

8.  Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.

Authors:  Wesley M Konsavage; Sydney L Kyler; Sherri A Rennoll; Ge Jin; Gregory S Yochum
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

9.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

10.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Authors:  Xiaodong Feng; Maria Sol Degese; Ramiro Iglesias-Bartolome; Jose P Vaque; Alfredo A Molinolo; Murilo Rodrigues; M Raza Zaidi; Bruce R Ksander; Glenn Merlino; Akrit Sodhi; Qianming Chen; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

View more
  14 in total

Review 1.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

2.  Upregulation of Yes-associated protein and transcriptional co-activator with PDZ-binding motif influences the behavior of LOVO human colon adenocarcinoma cells.

Authors:  Yu Li; Lan Li; Min Zhu; Limin Ye; Qian Yang
Journal:  Exp Ther Med       Date:  2017-08-18       Impact factor: 2.447

3.  A positive feedback regulation between long noncoding RNA SNHG1 and YAP1 modulates growth and metastasis in laryngeal squamous cell carcinoma.

Authors:  Ling Gao; Hua Cao; Xiulian Cheng
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

4.  DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.

Authors:  Dehai Wang; Zhongbo Li; Xin Li; Cheng Yan; Huijie Yang; Ting Zhuang; Xiao Wang; Yifeng Zang; Ziping Liu; Tianshi Wang; Rixia Jiang; Peng Su; Jian Zhu; Yinlu Ding
Journal:  J Exp Clin Cancer Res       Date:  2022-07-12

5.  A Middle-Out Modeling Strategy to Extend a Colon Cancer Logical Model Improves Drug Synergy Predictions in Epithelial-Derived Cancer Cell Lines.

Authors:  Eirini Tsirvouli; Vasundra Touré; Barbara Niederdorfer; Miguel Vázquez; Åsmund Flobak; Martin Kuiper
Journal:  Front Mol Biosci       Date:  2020-10-09

6.  SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis.

Authors:  Tingting Huang; Yuhang Zhou; Jinglin Zhang; Chi Chun Wong; Weilin Li; Johnny S H Kwan; Rui Yang; Aden K Y Chan; Yujuan Dong; Feng Wu; Bin Zhang; Alvin H K Cheung; William K K Wu; Alfred S L Cheng; Jun Yu; Nathalie Wong; Wei Kang; Ka Fai To
Journal:  Oncogene       Date:  2017-12-13       Impact factor: 9.867

7.  miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.

Authors:  Wei Kang; Tingting Huang; Yuhang Zhou; Jinglin Zhang; Raymond W M Lung; Joanna H M Tong; Anthony W H Chan; Bin Zhang; Chi Chun Wong; Feng Wu; Yujuan Dong; Shiyan Wang; Weiqin Yang; Yi Pan; Wing Po Chak; Alvin H K Cheung; Jesse C S Pang; Jun Yu; Alfred S L Cheng; Ka Fai To
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

Review 8.  Flaming the fight against cancer cells: the role of microRNA-93.

Authors:  Milad Ashrafizadeh; Masoud Najafi; Reza Mohammadinejad; Tahereh Farkhondeh; Saeed Samarghandian
Journal:  Cancer Cell Int       Date:  2020-06-29       Impact factor: 5.722

Review 9.  [Emerging roles of Hippo signaling pathway in gastrointestinal cancers and its molecular mechanisms].

Authors:  Yaoping Huang; Feng Yang; Tianhua Zhou; Shanshan Xie
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

10.  RIP140 and LCoR expression in gastrointestinal cancers.

Authors:  Mouna Triki; Dorra Ben Ayed-Guerfali; Ines Saguem; Slim Charfi; Lobna Ayedi; Tahia Sellami-Boudawara; Vincent Cavailles; Raja Mokdad-Gargouri
Journal:  Oncotarget       Date:  2017-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.